{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Renal Adverse Event Management', 'RENAL EVENTS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Grade 1', 'Consider withholding', 'Provide symptomatic treatment.', 'REGN2810 if event', 'Monitor creatinine weekly; when it returns to', 'Nephritis', 'Nephritis', 'does not improve with', 'baseline, resume routine creatinine monitoring', 'autoimmune', 'symptomatic', 'per protocol.', 'treatment', 'Systemic corticosteroids at a dose of', 'All attempts should', '1-2 mg/kg/day of prednisone or equivalent may', 'be made to rule out', 'be indicated. When symptoms improve to Grade', 'other causes such as', '1 or less, corticosteroid taper should be started', 'obstructive', 'Grade 2', 'Consider withholding', 'and continued over at least 1 month.', 'uropathy,', 'Renal failure', 'REGN2810', 'Consider prophylactic antibiotics for opportunistic', 'progression of', 'infections.', 'disease, or injury to', 'Consider renal biopsy.', 'other chemotherapy', 'If elevations persist >7 days or worsen, treat as', 'agents. A renal', 'Grade 4.', 'consultation is', 'recommended.', 'Renal consultation with consideration of', 'ultrasound and/or biopsy as appropriate.', 'Monitor creatinine daily.', 'Treat with systemic corticosteroids at a dose of 1-', '2 mg/kg prednisone or equivalent once per day.', 'Grade 3-4', 'Discontinue REGN2810', 'When symptoms improve to grade 1 or less,', 'Renal failure acute', 'steroid taper should be started and continued', 'over no less than 4 weeks.', 'Discontinue REGN2810 if unable to reduce', 'corticosteroid dose for irAEs to <10 mg.', 'REGN2810 treatment may be restarted and the', 'dose modified as specified in the protocol.', 'Regeneron Pharmaceuticals, Inc.', 'Page 125 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Hematologic Adverse Event Management', 'Thrombocyto', 'Cemiplimab Dosing', 'Diagnostic', 'penia', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Grade 1-2', 'No change in dose', 'See Table 4', 'Grade 3', 'See Table 4', 'Grade 4', 'Regeneron Pharmaceuticals, Inc.', 'Page 126 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Hematologic Adverse Event Management (Cont.)', 'Neutropenia', 'Cemiplimab Dosing', 'Diagnostic', 'CTCAE v4.03 Grade', 'Action and Guidelines', 'Management', 'Considerations', 'Grade 1-3', 'No change in dose', 'For neutropenia, see general guidelines on', 'hematological toxicity in Table 4', 'Hold until resolves to', 'Grade 1. May', 'increase the dosing', 'Grade 4', 'interval by 1 week.', 'For neutropenia, see general guidelines on', 'Discontinue if', 'hematological toxicity in Table 4', 'toxicities do not', 'resolve within', '12 weeks.', 'Regeneron Pharmaceuticals, Inc.', 'Page 127 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}